HOME >> BIOLOGY >> NEWS
Abgenix and Chiron enter Xenomouse Technology Collaboration, targets antibody products for autoimmune ,,disease and cancer

FREMONT, CALIF., December 1, 1999 - Abgenix, Inc. (Nasdaq: ABGX) today announced that it has signed a research license and option agreement with Chiron, Inc. ("Chiron") (Nasdaq: CHIR) under which Chiron will use Abgenix's XenoMouse™ technology to generate fully human monoclonal antibodies to an undisclosed antigen in the field of autoimmune diseases. In return, Abgenix will receive a technology access payment and could receive additional fees and milestone payments plus royalties on future product sales by Chiron. Under a separate research collaboration agreement, Chiron may use XenoMouse to generate fully human monoclonal antibodies on up to four cancer targets. Chiron will be responsible for product development, manufacturing, and marketing of any products developed through the collaboration.

"We are delighted to be working with Chiron, one of the world's leading biotechnology companies," stated R. Scott Greer, president and CEO of Abgenix. "Chiron becomes the fourteenth partner using our XenoMouse technology to generate antibody product candidates. This deal also represents the eighth new potential product candidate being pursued by one of our XenoMouse collaborators this year."

Abgenix is a biopharmaceutical company that develops and intends to commercialize antibody therapies for the treatment of such conditions as transplant-related diseases, inflammatory and autoimmune disorders, cardiovascular disease and cancer. Abgenix developed XenoMouse technology to enable the rapid generation of high affinity, fully human antibody product candidates to essentially any disease target appropriate for antibody therapy. Abgenix has collaborative arrangements with multiple pharmaceutical and biotechnology companies involving its XenoMouse technology. In addition, Abgenix has multiple proprietary antibody product candidates under development internally, three of which are in human clinical trials.


'"/>

Contact: Kurt Leutzinger, Abgenix, Inc.
510-608-6575
Porter Novelli
30-Nov-1999


Page: 1

Related biology news :

1. Abgenix to become sole owner of Xenomouse fully human antibody technology
2. Abgenix and CuraGen establish large-scale drug development alliance, companies to develop genomics-based human antibody drugs
3. Abgenix initiates phase III clinical trial of graft versus host disease therapy
4. Abgenix reports positive clinical data with ABX-IL8 in Psoriasis
5. Human Genome Sciences and Abgenix enter a broad collaboration to create fully human antibody therapeutics
6. Abgenix Reports Encouraging Preclinical Results With ABX-EGF In Cancer Research
7. Chiron reports on discovery of novel men B vaccine candidates based on whole genome sequencing of Neisseria meningitidis by TIGR
8. Chiron Discovers Significant Hepatitis C Binding Mechanism; Data Indicates CD81 Protein May Be A Virus Receptor
9. NIH awards $18.2m to The Burnham Institute to develop Center on Proteolytic Pathways
10. Schepens Eye Research Institute receives Roadmap grant to develop center for curing eye diseases
11. New Arizona State center brings science to policy on issues of water resources and urban growth

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/14/2018)... N.Y. (PRWEB) , ... August 13, 2018 , ... ... new 2017/18 products, the Staticmaster® P-2021-5502 and P-2021-5602 Cleanroom Ionizing Gun. , ... VTE-208 Filtered Nitrogen Air Gun, P-2021 ionizing cartridge, 0.5-micron filter and electropolished OSHA-compliant ...
(Date:8/14/2018)... ... August 14, 2018 , ... ... solutions for the global scientific community, announced today the establishment of a new ... division is to foster and support scientific collaborations with ActiGraph’s academic and pharmaceutical ...
(Date:8/14/2018)... ... August 14, 2018 , ... From reconstruction of craniofacial syndrome ... better understanding of congenital heart defects, 3-D printing is providing exciting approaches to ... of Birth Defects Research (DOI: 10.1002/bdr2.1367). , The special ...
Breaking Biology News(10 mins):
(Date:7/27/2018)... ... July 27, 2018 , ... ... of the Biotechnology Innovation Organization (BIO) met with U.S. Environmental Protection Agency ... a Toxic Substances Control Act (TSCA) Inventory Representation and Equivalency Determinations for ...
(Date:7/25/2018)... ... July 25, 2018 , ... Vium, Inc. http://www.vium.com ... and Vium Cloud approach to accelerate preclinical drug discovery and development, today announced ... announced the appointment of Jeff Caron to the newly formed role of Senior ...
(Date:7/24/2018)... ... July 23, 2018 , ... ... energy treated nutraceutical to increase immunity and improve anti-inflammatory, and immune function responses. ... assessed in the preclinical research were significantly reduced. Results are as follows:, ...
(Date:7/22/2018)... ... July 19, 2018 , ... CallTower ... joined their team. With more than ten years of strategic, result-oriented Channel experience ... expertise as CallTower’s Channel Director for the Southwest and Mountain region. , As ...
Breaking Biology Technology:
Cached News: